Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 133 Squamous Cell Carcinoma of Head and Neck 76 Lung Neoplasms 49 Head and Neck Neoplasms 45 Urinary Bladder Neoplasms 43 Parkinson Disease 4, Autosomal Dominant Lewy Body 33 Oropharyngeal Neoplasms 32 Nasopharyngeal Carcinoma 32 Biliary Tract Neoplasms 31 Uterine Cervical Neoplasms 30 Cholangiocarcinoma 28 Esophageal Squamous Cell Carcinoma 26 Carcinoma 24 Neoplasms 23 Ovarian Neoplasms 22 Neoplasm Metastasis 22 Small Cell Lung Carcinoma 21 Carcinoma, Squamous Cell 20 Stomach Neoplasms 18 Colorectal Neoplasms 18 Carcinoma, Transitional Cell 17 Pancreatic Neoplasms 16 Esophageal Neoplasms 16 Mesothelioma, Malignant 15 Gallbladder Neoplasms 15 Mouth Neoplasms 14 Laryngeal Neoplasms 13 Hypopharyngeal Neoplasms 12 Endometrial Neoplasms 11 Triple Negative Breast Neoplasms 10

Interventions

enfortumab vedotin 2 zimberelimab 1 sacituzumab govitecan 1 pembrolizumab 1 avelumab 1 Gemcitabine 1 Cisplatin 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Metastatic Urothelial Cancer × Cisplatin × 1 year × Clear all

NCT03547973 2026-03-16

TROPHY U-01

Gilead Sciences

Phase 2 Recruiting

827 enrolled 1 FDA

Metastatic Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡